News

TRIO is honored to welcome Mark Pegram, MD to the TRIO Breast Cancer Scientific Committee

Dr. Pegram is the Suzy Yuan-Huey Hung Endowed Professor of Medical Oncology at the Stanford University School of Medicine. He currently serves as the Associate Director of Clinical Research at…

TRIO ranks among Uruguay’s best workplaces in 2025 as chosen by Great Place to Work

For the third year in a row, the TRIO Latin American hub has ranked among the best workplaces in Uruguay by Great Place to Work®. At TRIO, we strive to…

US FDA Approves adjuvant ribociclib based on the results from the NATALEE (TRIO033) trial

Link to the News Article.

NATALEE (TRIO033) Phase III trial demonstrates ribociclib significantly reduces the risk of recurrence for patients with early breast cancer, at interim analysis

Translational Research In Oncology (TRIO) today announced positive topline results from NATALEE (TRIO033), a Novartis sponsored Phase III trial of ribociclib plus endocrine therapy (ET) as adjuvant treatment for patients…

TRIO is proud to be on the 2023 list of Canada’s Top Small and Medium Employers for the 3rd year in a row

For a third year in a row! We are very proud to be on a list with a great group of employers. Our people are what makes us great at…

TRIO ranks 4th among Uruguay’s best workplaces in 2023 as chosen by Great Place to Work™

After obtaining the Great Place to Work® certification in 2022, we are happy to announce that TRIO Uruguay has been ranked fourth among Uruguay’s best workplaces in 2023! The accolades…

TRIO Obtains the Great Place to Work® Certification in Uruguay

Translational Research in Oncology (TRIO), a global oncology clinical research organization, announced that its Uruguayan office has been recognized with the Great Place to Work® seal, awarded by the prestigious…

TRIO Named To Canada’s Top Employer List For Second Straight Year

Translational Research In Oncology (TRIO), a global academic clinical research organization, is pleased to be recognized as one of Canada’s top small & medium employers for the second straight year.…

TRIO Enrolls First Patient In Global Phase 3 Giredestrant Early Breast Cancer Trial

Translational Research in Oncology (TRIO), a global academic clinical research organization, announced today enrolment of first patient in the LidERA Breast Cancer (TRIO045) trial, a Phase 3 randomized, multi-center, open-label…

TRIO Completes Enrolment For Phase 2 Giredestrant Early Breast Cancer Trial Ahead Of Schedule

Translational Research in Oncology (TRIO), a global academic clinical research organization, announced today enrolment completion in coopERA Breast Cancer (WO42133/TRIO038), a Phase 2 randomized, multi-center, open-label clinical trial of giredestrant…